Recently, Chinese synthetic biomaterial startup PAM2LBiotechnologies completed an angel round of financing with a total amount of nearly US $5 million. The financing marks the official start of the company's research and development of new synthetic biological materials and related medical pipeline products.
PAM2LBiotechnologies uses synthetic biology and machine learning to develop sustainable bio-based materials, focusing on the industrial transformation of new materials in the fields of vascular intervention, wound closure and wound care. The aim is to improve the convenience of operation and reduce the burden and pain of patients.
The vast majority of the financing will be used for product development and industrial transformation. The company has recruited a number of core technical teams from home and abroad, including synthetic biotechnology, bioinformatics, metabolic engineering, immunology, and fermentation and purification industry engineering, to promote the orderly mass production of products under development. At the same time, PAM2LBiotechnologies is doing the relevant planning and construction of the GMP plant. It is planned that the products will enter the clinical stage within 10 months and will be available for sale within 2 to 3 years.